Niowave announced the groundbreaking of a new $75 million production facility in Lansing, Michigan, expanding its manufacturing footprint and strengthening domestic supply of Actinium‑225 (Ac‑225), an isotope used in targeted cancer therapies.
The investment will create approximately 70 jobs. The facility will feature multiple proprietary superconducting linear accelerators along with processing and quality systems, enabling reliable, scalable production of Ac-225.
Construction will begin at Niowave's Lansing campus and will be led by The Christman Company, in collaboration with Colliers Engineering & Design. The site is expected to become operational in 2028.
"This expansion reflects our continued commitment to advancing the future of targeted alpha therapy and investing in the Lansing community," said Mike Zamaira, Chief Executive Officer of Niowave. "Actinium-225 has the potential to transform cancer treatment, and this new facility significantly strengthens our ability to deliver this critical isotope so that therapies can reach patients who need them."
"Michigan grit and innovation is proving our state is the best place to think, build, and lead the future," said Governor Whitmer. "Niowave's expansion will create more than 70 good-paying local jobs in R&D, engineering, and quality assurance, and grow our supply of medical isotopes that are critical for lifesaving cancer medicine. I'm proud of the work we've done together to grow Michigan's economy and help Michigan companies develop the next big advancement in science and technology. Congratulations to Niowave. Let's keep building the future in Michigan."
Ac-225 is an alpha-emitting isotope central to the development of targeted cancer therapies designed to precisely destroy cancer cells while minimizing impact on healthy tissue. Interest from biopharmaceutical companies has grown rapidly, and Niowave has announced two major supply agreements in the last four months.
